A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been incorporated into various clinical oncology guidelines for systemic treatment of advanced non-small cell lung cancers (aNSCLC). However, less than 50% (and 20%) of the patients responded to the therapy as a first (or second) line of therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Ayers, Kristin L., Ma, Meng, Debussche, Gaspard, Corrigan, David, McCafferty, Jonathan, Lee, Kyeryoung, Newman, Scott, Zhou, Xiang, Hirsch, Fred R., Mack, Philip C., Liu, Jane J., Schadt, Eric E., Chen, Rong, Li, Shuyu D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059160/
https://www.ncbi.nlm.nih.gov/pubmed/33882890
http://dx.doi.org/10.1186/s12885-021-08194-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059160/
https://www.ncbi.nlm.nih.gov/pubmed/33882890
http://dx.doi.org/10.1186/s12885-021-08194-9

Ejemplares similares